SCA
HAE icon

Summit Creek Advisors’s Haemonetics HAE Stock Holding History

Summit Creek Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-131,860
Closed -$8.34M – 75
2022
Q1 		$8.34M Buy
131,860
+503
+0.4% +$27.4K 0.94% 43
2021
Q4 		$6.97M Buy
131,357
+3,574
+3% +$218K 0.7% 47
2021
Q3 		$9.02M Buy
127,783
+10,736
+9% +$677K 0.95% 46
2021
Q2 		$7.8M Sell
117,047
-4,315
-4% -$305K 0.93% 48
2021
Q1 		$13.5M Sell
121,362
-1,588
-1% -$197K 1.61% 36
2020
Q4 		$14.6M Sell
122,950
-7,560
-6% -$814K 1.87% 29
2020
Q3 		$11.4M Buy
130,510
+2,910
+2% +$254K 1.69% 29
2020
Q2 		$11.4M Buy
+127,600
New +$12.9M 1.68% 24

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
LCP
LGT Capital Partners Pfaeffikon, Switzerland $1.97B AUM 15.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Creek Advisors's HAE Position: Q2 2022 in Review

Summit Creek Advisors sold out of Haemonetics (HAE) in Q2 2022, closing a stake of 131,860 shares — an estimated $8.34M sold.

Summit Creek Advisors first reported a position in HAE in Q2 2020 and held it in 8 quarters. The position peaked at $14.6M in Q4 2020. 241 funds tracked by Wall St. Rank hold HAE as of Q2 2022.

  • Summit Creek Advisors reported no remaining Haemonetics position as of Q2 2022 after selling out during the quarter.
  • Summit Creek Advisors sold 131,860 Haemonetics shares in Q2 2022, an estimated $8.34M.
  • Summit Creek Advisors first reported a position in Haemonetics in Q2 2020 and held it in 8 quarters.
  • Summit Creek Advisors's Haemonetics position peaked at $14.6M in Q4 2020.
  • 241 funds tracked by Wall St. Rank held Haemonetics as of Q2 2022.

Based on Summit Creek Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.